H-GGGGSGGGS-OH

Ref. 3D-PP47678

Product Information

• Name: H-GGGGSGGGS-OH

Description

Peptide H-GGGGSGGGS-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-GGGGSGGGS-OH include the following: The flexible linker and CotG were more effective for the spore surface display of keratinase KERQ7 Z Wang, M Yan, M Saeed , K Li, Y Chen - World Journal of , 2024 - Springerhttps://link.springer.com/article/10.1007/s11274-023-03854-3 Novel RNA- or Antibody-Based Strategies Targeting Growth Factors in Prostate Cancer Y Fujita-Yamaguchi - 2001., 2001 - apps.dtic.milhttps://apps.dtic.mil/sti/citations/tr/ADA390412 The making of bispecific antibodies U Brinkmann , RE Kontermann - MAbs, 2017 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/19420862.2016.1268307 Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth SL Li, SJ Liang, N Guo, AM Wu - Cancer Immunology , 2000 - Springerhttps://link.springer.com/article/10.1007/s002620000115 Antiviral activity of a llama-derived single-domain antibody against enterovirus A71 PN Huang , HC Wang , HC Hung - Antimicrobial Agents , 2020 - Am Soc Microbiolhttps://journals.asm.org/doi/abs/10.1128/aac.01922-19 Serum immunoglobulin or albumin binding single-domain antibodies that enable tailored half-life extension of biologics in multiple animal species MM Harmsen, B Ackerschott, H De Smit - Frontiers in Immunology, 2024 - frontiersin.orghttps://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1346328 Preclinical characterization of HPN536, a trispecific, T-cell-activating protein construct for the treatment of mesothelin-expressing solid tumors ME Molloy, RJ Austin, BD Lemon, WH Aaron - Clinical Cancer , 2021 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/27/5/1452/84020 Potent and efficacious inhibition of CXCR2 signaling by biparatopic nanobodies combining two distinct modes of action ME Bradley, B Dombrecht, J Manini, J Willis - Molecular , 2015 - ASPEThttps://molpharm.aspetjournals.org/content/87/2/251.short Unique structure of ozoralizumab, a trivalent anti-TNFalpha NANOBODY® compound, offers the potential advantage of mitigating the risk of immune complex-induced M Kyuuma, A Kaku, C Mishima-Tsumagari - Frontiers in , 2023 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1149874/full A bioluminescent cell assay to quantify prion protein dimerization KA Wusten, PP Reddy, A Smiyakin, ME Bernis - Scientific Reports, 2018 - nature.comhttps://www.nature.com/articles/s41598-018-32581-1 Screening for promising multi-target bioactive components from Cortex Mori Radicis for the treatment of chronic cor pulmonale based on immobilized beta1 J Wang, Y He, S Che, J Fe - Journal of Chromatography B, 2024 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1570023224001843 Patent application title: NOVEL CHIMERIC POLYPEPTIDES FOR SCREENING AND DRUG DISCOVERY PURPOSES Inventors: Jan Steyaert (Beersel, BE) IPC Class, A USPC - 2015 - patentsencyclopedia.comhttps://www.patentsencyclopedia.com/app/20150376261 A leucine zipper motif of a tegument protein triggers final envelopment of human cytomegalovirus CS Meissner, S Suffner, M Schauflinger - Journal of , 2012 - Am Soc Microbiolhttps://journals.asm.org/doi/abs/10.1128/jvi.06556-11 Functional characterization of tobacco transcription factor TGA2. 1 C Kegler, I Lenk, S Krawczyk, R Scholz, C Gatz - Plant molecular biology, 2004 - Springerhttps://link.springer.com/article/10.1007/s11103-004-0110-9

• Brand: Biosynth